Essays in Corporate Finance
Files
Publication or External Link
Date
Authors
Citation
DRUM DOI
Abstract
Prior research has been divided regarding how firms respond to bankruptcy
risk, largely revolving around two competing forces. On the one hand, asset substitution
encourages firms to increase the riskiness of assets to extract value from
creditors. On the other, firms want to minimize bankruptcy risk, either by reducing
cash flow risk or through increasing the size of the firm.
I test these two theories using a natural experiment of chemicals used in production
processes being newly identified as carcinogenic to explore how firms may
respond to potential negative cash flow resulting from litigation risk. I use plantlevel
chemical data to study firm exposure to risk. I examine how responses between
firms of differing levels of chemical exposure may vary within the industry, how firm
financial distress affects firm response and whether public and private firms respond
differently. In general, my research provides support for the asset substitution theory.
My first paper studies how investment response varies based on level of carcinogenic
exposure. I find that firms with moderate levels of exposure make efforts
to mitigate their cash flow risk and reduce their exposure. At the same time, firms
with high levels of exposure increase their exposure and riskiness of future cash
flows. These findings are consistent with asset substitution theory.
My second paper analyzes the interaction of financial distress and risk exposure.
I find that firms in a stronger financial position are more likely to limit their
exposure by reducing the number of exposed facilities. On the other hand, not only
do firms in weaker financial position not decrease their exposure, I find that, in some
instances, they increase their exposure to carcinogens. This work again supports
the theory of asset substitution.
Finally, in my third paper, I explore if public firms respond differently to a
potential negative cash flow shock than do private firms. I test whether existing
public firms are more likely to attempt to minimize their cash flow risk and thus
reduce their carcinogen exposure than are private firms. I do not find evidence that
public firms respond differently to this shock than do private firms.